Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POP-ELA: Elacestrant in Early Breast Cancer
NCT07159451Phase 2Recruiting
- Sponsor
- Gustave Roussy
- Start
- Oct 2025
- Primary completion
- Jan 2027
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elacestrant in breast cancer (2 arms), sponsored by Gustave Roussy. Primary endpoint: Mean decrease in Ki67. Started Oct 2025; status: recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07159451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07159451.